BillionToOne should keep taking share from Natera because its products' efficacy is far ahead, and it has a good chance of becoming a $100B-plus company. Few companies grow this fast with such an intriguing business model while already profitable. A share price above $100 does not make it expensive, since it has fewer than 50M shares outstanding and price per share says nothing about size or upside. x.com  x.com  x.com 

Tempus AI's diagnostics-to-data-to-AI flywheel makes its roughly 7.2x forward sales interesting, about half Natera's and Guardant's 16x, though both grow faster. Q2 revenue rose 22% to $382.5M, Data Licensing & Modeling grew 36%, and 2026 guidance is about $1.6B of revenue and $65M of adjusted EBITDA. As a ~25% growth diagnostics company, ~7x may be reasonable; if growth reaccelerates toward 30%+, Data + Applications grows much larger and margins expand, the valuation could look very different. … Show more

BillionToOne is taking share in both prenatal testing and oncology thanks to patented technology that makes its tests more sensitive and specific. It is the only diagnostic peer that is GAAP profitable, and it may be best positioned to offer a genuinely useful early cancer detection test, adding optionality. On revenue it looks pricier, but its real comparables, Natera and Guardant Health, are about 50% more expensive while growing more slowly and earning less. x.com  x.com